Stay updated on Benralizumab in HES: Efficacy and Safety Clinical Trial
Sign up to get notified when there's something new on the Benralizumab in HES: Efficacy and Safety Clinical Trial page.

Latest updates to the Benralizumab in HES: Efficacy and Safety Clinical Trial page
- Check5 days agoNo Change Detected
- Check12 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.0%
- Check20 days agoNo Change Detected
- Check27 days agoChange DetectedThe web page has undergone significant changes, including the removal of detailed descriptions of a Phase III study on benralizumab for hypereosinophilic syndrome, while adding a new registry identifier and a masking description. The revision number has also been updated.SummaryDifference48%
- Check34 days agoChange DetectedThe web page has updated its version from v2.14.3 to v2.14.4, and a date has been added for February 13, 2025, while a date for March 25, 2025, has been removed.SummaryDifference0.2%
- Check42 days agoChange DetectedThe page has been updated to reflect a new version release, moving from v2.14.2 to v2.14.3, and the last update date has changed from February 13, 2025, to March 25, 2025.SummaryDifference0.2%
- Check78 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference0.8%
- Check85 days agoChange DetectedThe study has transitioned from a recruiting status to an active status, indicating that patient recruitment has concluded. Additionally, the study's timeline has been updated with new dates for the primary database lock and the open-label extension period.SummaryDifference46%
Stay in the know with updates to Benralizumab in HES: Efficacy and Safety Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Benralizumab in HES: Efficacy and Safety Clinical Trial page.